Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–60 of 301 records
Abatacept (Orencia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Anakinra (Kineret)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Neonatal-Onset Multisystem Inflammatory Disease
Certolizumab pegol (Cimzia)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Moderately to severely active rheumatoid arthritis
Aflibercept-Abzv (Enzeevu)
Protein medicineApproved in the United States (FDA)Expanded recordBelatacept (Nulojix)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prophylaxis of organ rejection
Insulin Human (Humulin R / Novolin 70/30 / Afrezza / Myxredlin / Novolin N / Humulin R U-500)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Glycemic control
Adalimumab-Ryvk (Simlandi)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
SIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. ( 1.1 ) Juvenile Idiopathic Arthritis (JIA): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Insulin Aspart-Szjj (Merilog)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Lispro-Aabc (Lyumjev)
Protein medicineApproved in the United States (FDA)Expanded recordPegfilgrastim-Pbbk (Fylnetra)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adaz (Hyrimoz)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Adbm (Cyltezo)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Atto (Amjevita)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Mrbb (Ahzantive)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)…
Agalsidase beta (Fabrazyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Denosumab-Kyqq (Aukelso / Bosaya)
Protein medicineApproved in the United States (FDA)Expanded recordGemtuzumab Ozogamicin (Mylotarg)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Newly-diagnosed CD33-positive acute myeloid leukemia
Metreleptin (Myalept)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The complications of leptin deficiency
Pegvisomant (Somavert)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acromegaly
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo)
Protein medicineApproved in the United States (FDA)Expanded recordTaliglucerase alfa (Elelyso)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease
Adalimumab-Aaty (Yuflyma)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Afzb (Abrilada)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Adalimumab-Aqvh (Yusimry)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Bwwd (Hadlima)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Fkjp (Hulio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. J uvenile Idiopathic Arthritis (JIA) ( 1.2 ) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Aflibercept-Boav (Eydenzelt)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Jbvf (Yesafili)
Protein medicineApproved in the United States (FDA)Expanded recordAflibercept-Yszy (Opuviz)
Protein medicineApproved in the United States (FDA)Expanded recordCalaspargase Pegol-Mknl (Asparlas)
Protein medicineApproved in the United States (FDA)Expanded recordCerliponase alfa (Brineura)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The loss of ambulation
Collagen, Soluble, Fish Skin (Massage Cream For Stretch Marks / Aoao Retinol Anti-Aging Box Set / A0a0 Rice Ceramide Anti Wrinkle Age Essence Box Set / Aoa0 Snail Ginseng Cream)
Protein medicineApproved in the United States (FDA)Expanded recordCrovalimab-Akkz (Piasky)
Protein medicineApproved in the United States (FDA)Expanded recordDarbepoetin alfa (Aranesp)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Anemia due
Denileukin Diftitox-Cxdl (Lymphir)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Adet (Ponlimsi)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Bnht (Conexxence / Bomyntra)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Dssb (Ospomyv / Xbryk)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Nxxp (Bilprevda / Bildyos)
Protein medicineApproved in the United States (FDA)Expanded recordFaricimab-Svoa (Vabysmo)
Protein medicineApproved in the United States (FDA)Expanded recordHydrolyzed Bovine Elastin (Base (Anubis Barcelona / Massage Cream For Stretch Marks / Anubis Barcelona Vital Line)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
INDICATIONS& USAGE Suitable for all types of skin damage due to stretching of the skin. Apply all over skin, concentrating on tummy, hips, thighs and bust.Massage liberally into skin twice daily.
Lecanemab-Irmb (Leqembi / Lecanemab / Leqembi Iqlik)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Alzheimer’s disease
Parathyroid Hormone (Natpara)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Temporarily relieves discomfort caused by kidney issues, including occasional mild to severe aches, urinary obstruction, intense nausea with or without vomiting, and inability to completely empty the bladder.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE, NOT FDA EVALUATED. This product is not intended to diagnose, treat, cure, or prevent any disease.
Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta)
Protein medicineApproved in the United States (FDA)Expanded recordAdalimumab-Aacf (Idacio)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
IDACIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
Aflibercept-Ayyh (Pavblu)
Protein medicineApproved in the United States (FDA)Expanded recordAmivantamab-Vmjw (Rybrevant)
Protein medicineApproved in the United States (FDA)Expanded recordBenzylpenicilloyl Polylysine (Pre-Pen)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The assessment of sensitization to penicillin
Bevacizumab-Awwb (Mvasi)
Protein medicineApproved in the United States (FDA)Expanded recordChoriogonadotropin alfa (Ovidrel)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who
Concizumab-Mtci (Alhemo)
Protein medicineApproved in the United States (FDA)Expanded recordCrizanlizumab-Tmca (Adakveo)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Qbde (Enoby / Xtrenbo)
Protein medicineApproved in the United States (FDA)Expanded recordElapegademase-Lvlr (Revcovi)
Protein medicineApproved in the United States (FDA)Expanded recordFilgrastim-Txid (Nypozi)
Protein medicineApproved in the United States (FDA)Expanded recordGlucarpidase (Voraxaze)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Toxic plasma methotrexate concentration
Golimumab-Sldi (Immgolis / Immgolis Intri)
Protein medicineApproved in the United States (FDA)Expanded recordHyaluronidase (Vitrase / Amphadase / Hydase / Hylenex Recombinant)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Amphadase ® is an endoglycosidase indicated as an adjuvant: • in subcutaneous fluid administration for achieving hydration ( 1.1 ) • to increase absorption and dispersion of other injected drugs ( 1.2 ) • in subcutaneous urography for improving resorption of radiopaque agents ( 1.3 ) 1.1 Subcutaneous Fluid Administration Amphadase ® is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2 Dispersion and Absorption of Injected Drugs Amphadase ® is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
Hyaluronidase-Nvhy (Opdivo Qvantig)
Protein medicineApproved in the United States (FDA)Expanded recordInfliximab-Qbtx (Ixifi)
Protein medicineApproved in the United States (FDA)Expanded record